APA (7th ed.) Citation

Russo, D., Schmitt, M., Pilorge, S., Stelljes, M., Kawakita, T., Teal, V. L., . . . Badshah, C. (2024). Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Haematology, 11(2), . https://doi.org/10.1016/S2352-3026(23)00344-7

Chicago Style (17th ed.) Citation

Russo, Domenico, et al. "Efficacy and Safety of Extended Duration Letermovir Prophylaxis in Recipients of Haematopoietic Stem-cell Transplantation at Risk of Cytomegalovirus Infection: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Haematology 11, no. 2 (2024). https://doi.org/10.1016/S2352-3026(23)00344-7.

MLA (9th ed.) Citation

Russo, Domenico, et al. "Efficacy and Safety of Extended Duration Letermovir Prophylaxis in Recipients of Haematopoietic Stem-cell Transplantation at Risk of Cytomegalovirus Infection: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Haematology, vol. 11, no. 2, 2024, https://doi.org/10.1016/S2352-3026(23)00344-7.